BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035542
- Locations
- ๐บ๐ธ
National Institute Of Clinical Research, Los Angeles, California, United States
๐บ๐ธDriscoll Children's Hospital/Division of Medical Education/William Riley, Corpus Christi, Texas, United States
๐บ๐ธMetro Health Medical Center, Cleveland, Ohio, United States
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035789
- Locations
- ๐บ๐ธ
Local Investigator, Seattle, Washington, United States
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: BMS 188667 (Abatacept)Drug: Placebo
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035529
- Locations
- ๐บ๐ธ
Local Institution, Madison, Wisconsin, United States
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 444
- Registration Number
- NCT00035152
- Locations
- ๐บ๐ธ
Hennepin County Medical Center, Minneapolis, Minnesota, United States
๐บ๐ธSiouxland Hematology/Oncology Associates, Sioux City, Iowa, United States
๐บ๐ธWellstar Cobb Hospital, Austell, Georgia, United States
A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- First Posted Date
- 2002-02-08
- Last Posted Date
- 2009-01-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT00030173
- Locations
- ๐บ๐ธ
UCLA Medical Center, Los Angeles, California, United States
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
- Conditions
- HIV Infections
- First Posted Date
- 2001-12-21
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00028301
- Locations
- ๐ง๐ช
University Hospital Gent, Gent, Belgium
๐ฆ๐ทCAICI, Rosario Santa Fe, Argentina
๐ง๐ชCHU Saint Pierre, Brussels, Belgium
A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor
- Conditions
- HIV Infections
- First Posted Date
- 2001-12-11
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT00028067
- Locations
- ๐น๐ญ
Ramathibodi Hosp, Bangkok, Thailand
๐น๐ญKhonkaen Univ, Khonkaen, Thailand
๐บ๐ธHealth for Life Clinic, Little Rock, Arkansas, United States
Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-08-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 300
- Registration Number
- NCT00002035
- Locations
- ๐บ๐ธ
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
๐บ๐ธAlbany Med College / AIDS Treatment Ctr, Albany, New York, United States
๐บ๐ธUniv of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00013897
- Locations
- ๐บ๐ธ
Associates in Research, Fort Myers, Florida, United States
๐บ๐ธThe CORE Ctr, Chicago, Illinois, United States
๐บ๐ธOhio State Univ Hosp, Columbus, Ohio, United States
Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT00002429
- Locations
- ๐บ๐ธ
NJCRI, Newark, New Jersey, United States
๐บ๐ธUniv of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
๐จ๐ฆClinique Medicale L'Actuele, Montreal, Quebec, Canada